Do you want to read an article? Please log in or register.
Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
N Engl J Med.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
doi: 10.1056/NEJMoa1905725.
Inflammatory Bowel Disease
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab
Inflamm Bowel Dis.
Favale A, Onali S, Caprioli F, Pugliese D, Armuzzi A, Macaluso FS, Orlando A, Viola A, Fries W, Rispo A, Castiglione F, Mocci G, Chicco F, Usai P, Calabrese E, Biancone L, Monteleone G, Fantini MC, Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
doi: 10.1093/ibd/izz057.
Inflammatory Bowel Disease
Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis
J Crohns Colitis.
Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K
doi: 10.1093/ecco-jcc/jjy149.
Further Publications
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis
Clin Gastroenterol Hepatol
Narula N, Wong ECL, Marshall JK, Colombel JF, Dulai PS, Reinisch W
doi: 10.1016/j.cgh.2021.07.038
Inflammatory Bowel Disease
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Inflamm Bowel Dis.
Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S
doi: 10.1093/ibd/izy323.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials
J Crohns Colitis.
Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W
doi: 10.1093/ecco-jcc/jjz031.
Inflammatory Bowel Disease
Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors
Am J Gastroenterol.
Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, DʼHaens G, Feagan BG, Sandborn WJ, Jairath V, Singh S
doi: 10.14309/ajg.0000000000000596.
Inflammatory Bowel Disease
Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers
Aliment Pharmacol Ther.
Keshteli AH, Madsen KL, Mandal R, Boeckxstaens GE, Bercik P, De Palma G, Reed DE, Wishart D, Vanner S, Dieleman LA
doi: 10.1111/apt.15141.